Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BerGenBio AGM Information 2022

Jan 6, 2022

3555_rns_2022-01-06_bb6db763-87dc-4686-992a-94590daba5b6.html

AGM Information

Open in viewer

Opens in your device viewer

BerGenBio ASA: Extraordinary General Meeting held

BerGenBio ASA: Extraordinary General Meeting held

Bergen, Norway, 6 January 2022 - BerGenBio ASA (OSE:BGBIO) announces that an

extraordinary general meeting in the Company was held on 6 January 2022.

All proposals were resolved as presented in the notice convening the

extraordinary general meeting distributed on 16 December 2022, as further set

out in the minutes from the extraordinary general meeting attached hereto and

available at https://www.bergenbio.com/investors/general-

meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

-Ends-

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA

[email protected]

Rune Skeie, CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.